Breaking News

Biohaven Acquires Remaining Stake in Kleo Pharmaceuticals

Enters exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from Spiegel Lab.

By: Contract Pharma

Contract Pharma Staff

Biohaven Pharmaceutical Holding Co. Ltd. has acquired the remaining 58% interest of Kleo Pharmaceuticals, Inc. and has entered an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven assumed Kleo’s laboratory facilities located in Science Park in New Haven, CT and formed Biohaven Labs to serve as the integrated chemistry and discovery research arm of Biohaven.   ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters